Trial Library is a clinical trials company focused on oncology, dedicated to enhancing health equity through innovative technology. By promoting inclusive research environments, the company aims to improve health outcomes and transform standards of care in cancer treatment. Its technology facilitates equitable recruitment for clinical trials, ensuring broader access to precision medicine for diverse populations. Through these efforts, Trial Library addresses existing inequities in cancer research and care, ultimately striving to accelerate advancements in clinical trial participation and outcomes.
Rivet Health, Inc. is a company specializing in healthcare revenue cycle management through its software-as-a-service platform. Founded in 2018 and based in Cottonwood Heights, Utah, Rivet provides tools that enhance financial transparency and operational efficiency for healthcare providers and patients. Its offerings include features that allow providers to quote and collect patient costs upfront and manage payer contracts effectively. The software also helps patients understand their financial responsibilities, detect underpayments, and create accurate estimates, thereby fostering better communication between providers and payers. By addressing the complexities of healthcare transactions, Rivet aims to improve the overall experience for both patients and providers.
Miga is a virtual cardiometabolic clinic that focuses on improving heart health through an innovative platform that combines gamified mobile applications with comprehensive clinical services. Founded by Jarrad Aguirre, MD, and Dre Limberopoulos, Miga's offerings include at-home monitoring for blood pressure, telemedicine consultations, mail-order pharmacy services, and lifestyle coaching. The clinic addresses various cardiometabolic conditions such as obesity, hypertension, diabetes, and hyperlipidemia, empowering patients to manage their health effectively and reduce the risk of serious heart issues, including premature heart attacks and strokes.
Plexium, Inc. is a biotechnology company based in San Diego, California, established in 2017. The company specializes in drug development, focusing on the identification of small molecules that modulate E3 ligases for therapeutic applications in cancer and neurodegenerative diseases. Plexium employs a DNA-encoded library platform to conduct high-throughput screening, utilizing cell-based assays to discover molecular glues that can alter E3 ligase substrate recognition, thereby inducing, inhibiting, or modulating protein degradation. This innovative approach allows Plexium to selectively target various cancers, including small cell lung and breast tumors, while also exploring mechanisms to enhance immune responses through E3 ligase modulation.
Eikon Therapeutics is a biopharmaceutical company focused on developing innovative treatments for chronic and life-threatening diseases. Founded in 2019 and based in Hayward, California, the company utilizes advanced super-resolution microscopy technology to conduct live-cell and single-molecule imaging. This cutting-edge approach allows for real-time, molecular-resolution measurements of protein movement within living cells, enabling the identification of previously intractable drug targets. By directly measuring the interactions between chemical compounds and individual proteins in a cellular environment, Eikon Therapeutics aims to unlock new avenues for drug discovery and address complex health challenges.
Nplex Biosciences is a biotechnology company based in the United States that specializes in proteomic technology. The company has developed a platform that utilizes DNA nanotechnology to understand, detect, and treat diseases. Nplex offers a range of instruments and automation tools for measuring multiple proteins from blood samples, providing cost-effective solutions for protein data analysis. Its technology integrates seamlessly with industry-standard cytometers, enabling high-throughput analysis and the development of custom protein panels. Nplex aims to enhance existing instruments and workflows while facilitating automation in proteomic research and applications.
H1 is the developer of a healthcare data analytics platform intended to help companies make smarter scientific decisions. The company specializes in providing real-time data to support the end-to-end therapeutic development process from fundraising to product development to product launch, thereby providing the healthcare industry, organizations, and professionals with on-demand, live insights from across the data universe to accelerate the discovery and development of therapies to fight diseases.
Science 37, Inc. is a technology-driven clinical trial company focused on transforming clinical research through patient-centric models. It has developed NORA (Network Oriented Research Assistant), a cloud-based mobile research platform that facilitates communication between researchers and patients via videos, photographs, and surveys, enabling end-to-end networked clinical trial services. The company also offers the Science 37 Metasite, which enhances access to diverse patient populations for clinical studies, and the Science 37 Platform for decentralized clinical trials. By utilizing its virtual model, Science 37 has demonstrated faster enrollment and higher patient retention, reaching a broader and more representative patient demographic than traditional site-based research. The company serves a wide range of clients, including large pharmaceutical firms, biotechnology companies, universities, and startups. Since its incorporation in 2014, Science 37 has established itself as a leader in virtual clinical trials, leveraging an extensive network of telemedicine investigators and home-health nurses to conduct more decentralized interventional trials than any other organization.
A-Alpha Bio, Inc., founded in 2017 and based in Seattle, Washington, specializes in synthetic biology with a focus on drug development that targets multiple proteins. The company's flagship platform, AlphaSeq, offers innovative cell-based tools for quantitative and high-throughput measurement of protein interactions. This technology accelerates processes such as target discovery, library screening, and preclinical drug characterization, addressing significant bottlenecks in the industry. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in enhancing binding and specificity for various target proteins. The team comprises experts in synthetic biology, structural biology, and next-generation sequencing, all dedicated to advancing drug discovery methodologies.
AllStripes is a healthcare technology company dedicated to unlocking new treatments for people with rare disease. AllStripes has developed a two-sided platform that empowers patients to access and benefit from their own medical records and generates regulatory-ready evidence for life sciences companies.
Carbon Health is a tech-enabled healthcare company founded in 2015 and headquartered in San Francisco, California. It provides a mobile application that facilitates primary care services, allowing users to manage their treatment plans, prescriptions, and lab reports in one place. The company offers omnichannel care through various access points, including clinics, pop-up sites, video consultations, and its application, ensuring convenient and accessible healthcare for patients. Additionally, Carbon Health developed a coronavirus assessment tool and has established COVID-19 testing sites in California, further enhancing its commitment to delivering comprehensive healthcare services.
Dyno Therapeutics Inc. specializes in the development of adeno-associated virus (AAV) vectors for in vivo delivery of gene therapies. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes an artificial intelligence-driven approach that integrates DNA synthesis, sequencing, and machine learning. This innovative methodology enables the design of novel gene vectors with an emphasis on cell-targeting capsid proteins derived from AAV, which is recognized as the most commonly used vector in gene therapy applications. By leveraging quantitative high-throughput in vivo experimentation, Dyno Therapeutics aims to enhance the effectiveness and precision of gene therapy solutions.
Eikon Therapeutics is a biopharmaceutical company focused on developing innovative treatments for chronic and life-threatening diseases. Founded in 2019 and based in Hayward, California, the company utilizes advanced super-resolution microscopy technology to conduct live-cell and single-molecule imaging. This cutting-edge approach allows for real-time, molecular-resolution measurements of protein movement within living cells, enabling the identification of previously intractable drug targets. By directly measuring the interactions between chemical compounds and individual proteins in a cellular environment, Eikon Therapeutics aims to unlock new avenues for drug discovery and address complex health challenges.
Developer of a birth control optimization test designed to help determine which method of birth control is the best fit for anybody in order to minimize side effects. The company provides medically actionable scientific insights to find the right type of birth control, enabling women to proactively optimize their health-from birth control to fertility, and beyond.
SteadyMD, Inc. is a telehealth company based in St. Louis, Missouri, providing online primary care services across the United States. Founded in 2016, the company connects patients with doctors through its platform, allowing for telehealth consultations focused on various medical conditions, dietary preferences, and lifestyle choices. Utilizing a proprietary Matching Engine, SteadyMD pairs members with doctors based on hundreds of attributes to foster long-term relationships. The platform offers services in primary care, functional medicine, pediatric care, and employer health solutions, and is licensed to operate in all 50 states. Patients can conveniently communicate with their doctors via text, phone, or video chat, while the medical team manages health records, referrals to specialists, and coordination of tests and procedures, ensuring comprehensive and personalized care.
DeepSpin GmbH, founded in 2019 and headquartered in Berlin, Germany, specializes in the development of an innovative artificial intelligence (AI)-based magnetic resonance imaging (MRI) system. This next-generation imaging machine is designed to be significantly smaller, lighter, and more affordable than conventional MRI systems. By utilizing generative topological design for its hardware and deep learning algorithms for image processing, DeepSpin aims to enhance the accessibility of medical imaging, making it available to patients worldwide. The company's technology seeks to modernize medical imaging, providing a standard of care that can reach previously underserved medical domains.
Plexium, Inc. is a biotechnology company based in San Diego, California, established in 2017. The company specializes in drug development, focusing on the identification of small molecules that modulate E3 ligases for therapeutic applications in cancer and neurodegenerative diseases. Plexium employs a DNA-encoded library platform to conduct high-throughput screening, utilizing cell-based assays to discover molecular glues that can alter E3 ligase substrate recognition, thereby inducing, inhibiting, or modulating protein degradation. This innovative approach allows Plexium to selectively target various cancers, including small cell lung and breast tumors, while also exploring mechanisms to enhance immune responses through E3 ligase modulation.
H1 is the developer of a healthcare data analytics platform intended to help companies make smarter scientific decisions. The company specializes in providing real-time data to support the end-to-end therapeutic development process from fundraising to product development to product launch, thereby providing the healthcare industry, organizations, and professionals with on-demand, live insights from across the data universe to accelerate the discovery and development of therapies to fight diseases.
Workit Health, Inc. is a healthcare technology company that specializes in digital treatment for substance use disorders. Founded in 2014 and headquartered in Ann Arbor, Michigan, Workit Health offers an online platform that combines interactive therapeutic content with professional counseling services. The platform provides evidence-based treatment for opioid and alcohol use disorders, including medication-assisted treatment with buprenorphine. Users can access therapeutic recovery curriculums, video consultations with clinicians, online recovery groups, and virtual drug testing from the privacy of their homes. Workit Health serves a diverse range of clients, including employers, schools, hospitals, clinics, and recovery support communities, with additional locations in California, New Jersey, Alaska, and Washington.
EverlyWell develops do-it-yourself kits for a vast range of at-home regulatory-compliant diagnostic tests including food sensitivity, fertility, hormones, STDs, thyroid, and metabolism among the others, allowing users to perform tests at home and receive physician-reviewed results and insights on their mobile devices. EverlyWell also provides at-home covid testing.
Auransa is an AI-driven platform for discovering drugs of novel pharmacology from vast amounts of genomics data collected from human disease tissues. The company's platform is used to study molecular disease subtypes and predict compounds and targets for responder patient population. Current internal drug pipeline includes cancer and other diseases. The company has partnership with companies and institutions in biopharma industry.
Science 37, Inc. is a technology-driven clinical trial company focused on transforming clinical research through patient-centric models. It has developed NORA (Network Oriented Research Assistant), a cloud-based mobile research platform that facilitates communication between researchers and patients via videos, photographs, and surveys, enabling end-to-end networked clinical trial services. The company also offers the Science 37 Metasite, which enhances access to diverse patient populations for clinical studies, and the Science 37 Platform for decentralized clinical trials. By utilizing its virtual model, Science 37 has demonstrated faster enrollment and higher patient retention, reaching a broader and more representative patient demographic than traditional site-based research. The company serves a wide range of clients, including large pharmaceutical firms, biotechnology companies, universities, and startups. Since its incorporation in 2014, Science 37 has established itself as a leader in virtual clinical trials, leveraging an extensive network of telemedicine investigators and home-health nurses to conduct more decentralized interventional trials than any other organization.
Thrive Earlier Detection Corp. is a healthcare company dedicated to improving cancer detection through innovative technology. It focuses on the development of CancerSEEK, a liquid biopsy test that analyzes genomic mutations in tumor DNA and protein markers in plasma to identify multiple types of cancer at their earliest stages, often before symptoms become apparent. Founded in 2018 and headquartered in Cambridge, Massachusetts, with an additional office in Baltimore, Maryland, Thrive aims to integrate early cancer detection into routine medical care. The company was previously known as Thrive Sciences Inc. and has been a subsidiary of Exact Sciences Corporation since early 2021. Thrive was launched with support from various investors, including Third Rock Ventures and Section 32, reflecting a strong commitment to advancing cancer diagnostics.
Braid Health, Inc. is a San Francisco-based company founded in 2018 that specializes in developing artificial intelligence-based diagnostic tools for the radiology sector. The company aims to enhance medical imaging by combining AI-powered diagnostics with the expertise of board-certified radiologists. Braid Health's solutions facilitate real-time quality assurance, integration with Electronic Health Records (EHR), and improved imaging interpretation. By leveraging these technologies, Braid Health enables healthcare providers to diagnose patients more effectively, ultimately aiming to improve the overall quality of patient care.
AllStripes is a healthcare technology company dedicated to unlocking new treatments for people with rare disease. AllStripes has developed a two-sided platform that empowers patients to access and benefit from their own medical records and generates regulatory-ready evidence for life sciences companies.
AllStripes is a healthcare technology company dedicated to unlocking new treatments for people with rare disease. AllStripes has developed a two-sided platform that empowers patients to access and benefit from their own medical records and generates regulatory-ready evidence for life sciences companies.
Avail Medsystems, Inc. is a medical technology company based in Palo Alto, California, focused on enhancing connectivity in healthcare settings through its innovative software platform. This platform allows healthcare experts to remotely support practitioners during medical procedures, facilitating real-time collaboration and clinical education. By digitizing the physical presence typically required in operating rooms, Avail Medsystems aims to democratize access to essential clinical expertise, thereby overcoming physical, economic, and logistical barriers. The company's Procedural Telemedicine solution enables healthcare professionals to connect seamlessly with remote specialists, ensuring that quality care and guidance are always accessible. Founded in 2012 and formerly known as Nurep, Inc., Avail Medsystems has positioned itself at the forefront of integrating technology into medical practices.
Rivet Health, Inc. is a company specializing in healthcare revenue cycle management through its software-as-a-service platform. Founded in 2018 and based in Cottonwood Heights, Utah, Rivet provides tools that enhance financial transparency and operational efficiency for healthcare providers and patients. Its offerings include features that allow providers to quote and collect patient costs upfront and manage payer contracts effectively. The software also helps patients understand their financial responsibilities, detect underpayments, and create accurate estimates, thereby fostering better communication between providers and payers. By addressing the complexities of healthcare transactions, Rivet aims to improve the overall experience for both patients and providers.
Developer of disease-altering therapies intended for the treatment of neurodegenerative diseases. The company develops viral tools and platforms to screen for the targets with functional impact on neurodegenerative disease progression as well as offers functional genetic screening and multi-omics approaches to develop precision medicine, enabling healthcare professionals to treat patients with neurodegenerative diseases.
HumanFirst, formerly known as Elektra Labs, is a healthcare-security company based in Tyngsboro, Massachusetts, that focuses on enhancing healthcare operations in home settings. Established in 2017, the company has developed a digital measures platform called Atlas, which streamlines the evaluation and implementation of connected technologies for collecting behavioral and physiological data. HumanFirst caters to a diverse clientele, including leading organizations involved in decentralized clinical trials and virtual care. Notably, 22 of the 25 largest pharmaceutical companies globally have utilized the HumanFirst platform to assess and facilitate the deployment of health technology products. The company provides command center and infrastructure solutions that ensure the reliability and trustworthiness of telehealth operations, matching the standards typically found in hospitals and laboratories.
Variant Bio is leveraging the power of human genetic diversity to discover new therapeutics. The company's focus is to identify individuals and populations around the world who are extreme outliers for traits of medical relevance and to use innovative sequencing and analytic approaches to identify genes and pathways linked to these traits.
It was founded in 2018 and headquartered in Seattle, Washington.
Cala Health, Inc. is a bioelectronic medicine company focused on developing innovative therapies for chronic diseases. Based in Burlingame, California, the company specializes in wearable neuromodulation devices that utilize advancements in neuroscience and technology to provide individualized peripheral nerve stimulation. Its flagship product, Cala Trio, is a non-invasive therapy designed to offer relief from hand tremors in adults with essential tremor, a condition affecting millions. In addition to its current offerings, Cala Health is actively developing new therapeutic solutions in the fields of neurology, cardiology, and psychiatry, aiming to enhance the standard of care for patients with chronic conditions. Founded in 2013, the company has garnered support from prominent investors in both the healthcare and technology sectors.
Workit Health, Inc. is a healthcare technology company that specializes in digital treatment for substance use disorders. Founded in 2014 and headquartered in Ann Arbor, Michigan, Workit Health offers an online platform that combines interactive therapeutic content with professional counseling services. The platform provides evidence-based treatment for opioid and alcohol use disorders, including medication-assisted treatment with buprenorphine. Users can access therapeutic recovery curriculums, video consultations with clinicians, online recovery groups, and virtual drug testing from the privacy of their homes. Workit Health serves a diverse range of clients, including employers, schools, hospitals, clinics, and recovery support communities, with additional locations in California, New Jersey, Alaska, and Washington.
Science 37, Inc. is a technology-driven clinical trial company focused on transforming clinical research through patient-centric models. It has developed NORA (Network Oriented Research Assistant), a cloud-based mobile research platform that facilitates communication between researchers and patients via videos, photographs, and surveys, enabling end-to-end networked clinical trial services. The company also offers the Science 37 Metasite, which enhances access to diverse patient populations for clinical studies, and the Science 37 Platform for decentralized clinical trials. By utilizing its virtual model, Science 37 has demonstrated faster enrollment and higher patient retention, reaching a broader and more representative patient demographic than traditional site-based research. The company serves a wide range of clients, including large pharmaceutical firms, biotechnology companies, universities, and startups. Since its incorporation in 2014, Science 37 has established itself as a leader in virtual clinical trials, leveraging an extensive network of telemedicine investigators and home-health nurses to conduct more decentralized interventional trials than any other organization.
Eikon Therapeutics is a biopharmaceutical company focused on developing innovative treatments for chronic and life-threatening diseases. Founded in 2019 and based in Hayward, California, the company utilizes advanced super-resolution microscopy technology to conduct live-cell and single-molecule imaging. This cutting-edge approach allows for real-time, molecular-resolution measurements of protein movement within living cells, enabling the identification of previously intractable drug targets. By directly measuring the interactions between chemical compounds and individual proteins in a cellular environment, Eikon Therapeutics aims to unlock new avenues for drug discovery and address complex health challenges.
Auris Health, Inc. is a company based in Redwood City, California, focused on developing advanced robotics technology for medical applications. Founded in 2007, it specializes in creating innovative solutions for diagnostic and therapeutic bronchoscopic procedures. The company's flagship product, the Monarch Platform, utilizes small cameras and instruments to facilitate endoscopic procedures through natural body openings. This platform incorporates cutting-edge advancements in imaging technology, robotics, endoscope design, sensing, and data science, aiming to enhance patient outcomes and reduce medical costs. Additionally, Auris Health is developing a dual-arm microsurgical system designed for ophthalmic surgery, further expanding its capabilities in the medical robotics field. As a subsidiary of Johnson & Johnson, Auris Health continues to transform medical intervention through its integration of various technological innovations.
Visla Labs Inc. is a San Francisco-based company that specializes in developing an artificial intelligence platform tailored for the radiology and healthcare sectors. Founded in 2018, the company focuses on enhancing medical diagnostics through advanced AI technologies, aiming to improve the efficiency and accuracy of radiological assessments.
Braid Health, Inc. is a San Francisco-based company founded in 2018 that specializes in developing artificial intelligence-based diagnostic tools for the radiology sector. The company aims to enhance medical imaging by combining AI-powered diagnostics with the expertise of board-certified radiologists. Braid Health's solutions facilitate real-time quality assurance, integration with Electronic Health Records (EHR), and improved imaging interpretation. By leveraging these technologies, Braid Health enables healthcare providers to diagnose patients more effectively, ultimately aiming to improve the overall quality of patient care.
AllStripes is a healthcare technology company dedicated to unlocking new treatments for people with rare disease. AllStripes has developed a two-sided platform that empowers patients to access and benefit from their own medical records and generates regulatory-ready evidence for life sciences companies.
Rivet Health, Inc. is a company specializing in healthcare revenue cycle management through its software-as-a-service platform. Founded in 2018 and based in Cottonwood Heights, Utah, Rivet provides tools that enhance financial transparency and operational efficiency for healthcare providers and patients. Its offerings include features that allow providers to quote and collect patient costs upfront and manage payer contracts effectively. The software also helps patients understand their financial responsibilities, detect underpayments, and create accurate estimates, thereby fostering better communication between providers and payers. By addressing the complexities of healthcare transactions, Rivet aims to improve the overall experience for both patients and providers.
Auris Health, Inc. is a company based in Redwood City, California, focused on developing advanced robotics technology for medical applications. Founded in 2007, it specializes in creating innovative solutions for diagnostic and therapeutic bronchoscopic procedures. The company's flagship product, the Monarch Platform, utilizes small cameras and instruments to facilitate endoscopic procedures through natural body openings. This platform incorporates cutting-edge advancements in imaging technology, robotics, endoscope design, sensing, and data science, aiming to enhance patient outcomes and reduce medical costs. Additionally, Auris Health is developing a dual-arm microsurgical system designed for ophthalmic surgery, further expanding its capabilities in the medical robotics field. As a subsidiary of Johnson & Johnson, Auris Health continues to transform medical intervention through its integration of various technological innovations.
Science 37, Inc. is a technology-driven clinical trial company focused on transforming clinical research through patient-centric models. It has developed NORA (Network Oriented Research Assistant), a cloud-based mobile research platform that facilitates communication between researchers and patients via videos, photographs, and surveys, enabling end-to-end networked clinical trial services. The company also offers the Science 37 Metasite, which enhances access to diverse patient populations for clinical studies, and the Science 37 Platform for decentralized clinical trials. By utilizing its virtual model, Science 37 has demonstrated faster enrollment and higher patient retention, reaching a broader and more representative patient demographic than traditional site-based research. The company serves a wide range of clients, including large pharmaceutical firms, biotechnology companies, universities, and startups. Since its incorporation in 2014, Science 37 has established itself as a leader in virtual clinical trials, leveraging an extensive network of telemedicine investigators and home-health nurses to conduct more decentralized interventional trials than any other organization.
Science 37, Inc. is a technology-driven clinical trial company focused on transforming clinical research through patient-centric models. It has developed NORA (Network Oriented Research Assistant), a cloud-based mobile research platform that facilitates communication between researchers and patients via videos, photographs, and surveys, enabling end-to-end networked clinical trial services. The company also offers the Science 37 Metasite, which enhances access to diverse patient populations for clinical studies, and the Science 37 Platform for decentralized clinical trials. By utilizing its virtual model, Science 37 has demonstrated faster enrollment and higher patient retention, reaching a broader and more representative patient demographic than traditional site-based research. The company serves a wide range of clients, including large pharmaceutical firms, biotechnology companies, universities, and startups. Since its incorporation in 2014, Science 37 has established itself as a leader in virtual clinical trials, leveraging an extensive network of telemedicine investigators and home-health nurses to conduct more decentralized interventional trials than any other organization.
Workit Health, Inc. is a healthcare technology company that specializes in digital treatment for substance use disorders. Founded in 2014 and headquartered in Ann Arbor, Michigan, Workit Health offers an online platform that combines interactive therapeutic content with professional counseling services. The platform provides evidence-based treatment for opioid and alcohol use disorders, including medication-assisted treatment with buprenorphine. Users can access therapeutic recovery curriculums, video consultations with clinicians, online recovery groups, and virtual drug testing from the privacy of their homes. Workit Health serves a diverse range of clients, including employers, schools, hospitals, clinics, and recovery support communities, with additional locations in California, New Jersey, Alaska, and Washington.
3Scan, Inc. specializes in developing advanced microscopy tools and software for automated tissue sectioning and imaging, primarily aimed at enhancing large-scale sample analysis and 3D visualizations. Founded in 2010 and based in San Francisco, California, the company focuses on addressing diseases that manifest at the tissue level, including cancer, heart disease, and neurodegenerative disorders. By integrating automation, machine learning, and computer vision, 3Scan's technology enables researchers and medical professionals to achieve greater throughput, improved quantification, and extensive image analysis compared to traditional histopathology methods. This data-driven approach aims to deepen the understanding of tissue biology, facilitating the discovery of new diagnostics and therapeutics. 3Scan was acquired by Transcriptic, Inc. in 2019.
Cala Health, Inc. is a bioelectronic medicine company focused on developing innovative therapies for chronic diseases. Based in Burlingame, California, the company specializes in wearable neuromodulation devices that utilize advancements in neuroscience and technology to provide individualized peripheral nerve stimulation. Its flagship product, Cala Trio, is a non-invasive therapy designed to offer relief from hand tremors in adults with essential tremor, a condition affecting millions. In addition to its current offerings, Cala Health is actively developing new therapeutic solutions in the fields of neurology, cardiology, and psychiatry, aiming to enhance the standard of care for patients with chronic conditions. Founded in 2013, the company has garnered support from prominent investors in both the healthcare and technology sectors.
Science 37, Inc. is a technology-driven clinical trial company focused on transforming clinical research through patient-centric models. It has developed NORA (Network Oriented Research Assistant), a cloud-based mobile research platform that facilitates communication between researchers and patients via videos, photographs, and surveys, enabling end-to-end networked clinical trial services. The company also offers the Science 37 Metasite, which enhances access to diverse patient populations for clinical studies, and the Science 37 Platform for decentralized clinical trials. By utilizing its virtual model, Science 37 has demonstrated faster enrollment and higher patient retention, reaching a broader and more representative patient demographic than traditional site-based research. The company serves a wide range of clients, including large pharmaceutical firms, biotechnology companies, universities, and startups. Since its incorporation in 2014, Science 37 has established itself as a leader in virtual clinical trials, leveraging an extensive network of telemedicine investigators and home-health nurses to conduct more decentralized interventional trials than any other organization.
Auris Health, Inc. is a company based in Redwood City, California, focused on developing advanced robotics technology for medical applications. Founded in 2007, it specializes in creating innovative solutions for diagnostic and therapeutic bronchoscopic procedures. The company's flagship product, the Monarch Platform, utilizes small cameras and instruments to facilitate endoscopic procedures through natural body openings. This platform incorporates cutting-edge advancements in imaging technology, robotics, endoscope design, sensing, and data science, aiming to enhance patient outcomes and reduce medical costs. Additionally, Auris Health is developing a dual-arm microsurgical system designed for ophthalmic surgery, further expanding its capabilities in the medical robotics field. As a subsidiary of Johnson & Johnson, Auris Health continues to transform medical intervention through its integration of various technological innovations.
3Scan, Inc. specializes in developing advanced microscopy tools and software for automated tissue sectioning and imaging, primarily aimed at enhancing large-scale sample analysis and 3D visualizations. Founded in 2010 and based in San Francisco, California, the company focuses on addressing diseases that manifest at the tissue level, including cancer, heart disease, and neurodegenerative disorders. By integrating automation, machine learning, and computer vision, 3Scan's technology enables researchers and medical professionals to achieve greater throughput, improved quantification, and extensive image analysis compared to traditional histopathology methods. This data-driven approach aims to deepen the understanding of tissue biology, facilitating the discovery of new diagnostics and therapeutics. 3Scan was acquired by Transcriptic, Inc. in 2019.
Cala Health, Inc. is a bioelectronic medicine company focused on developing innovative therapies for chronic diseases. Based in Burlingame, California, the company specializes in wearable neuromodulation devices that utilize advancements in neuroscience and technology to provide individualized peripheral nerve stimulation. Its flagship product, Cala Trio, is a non-invasive therapy designed to offer relief from hand tremors in adults with essential tremor, a condition affecting millions. In addition to its current offerings, Cala Health is actively developing new therapeutic solutions in the fields of neurology, cardiology, and psychiatry, aiming to enhance the standard of care for patients with chronic conditions. Founded in 2013, the company has garnered support from prominent investors in both the healthcare and technology sectors.
Auris Health, Inc. is a company based in Redwood City, California, focused on developing advanced robotics technology for medical applications. Founded in 2007, it specializes in creating innovative solutions for diagnostic and therapeutic bronchoscopic procedures. The company's flagship product, the Monarch Platform, utilizes small cameras and instruments to facilitate endoscopic procedures through natural body openings. This platform incorporates cutting-edge advancements in imaging technology, robotics, endoscope design, sensing, and data science, aiming to enhance patient outcomes and reduce medical costs. Additionally, Auris Health is developing a dual-arm microsurgical system designed for ophthalmic surgery, further expanding its capabilities in the medical robotics field. As a subsidiary of Johnson & Johnson, Auris Health continues to transform medical intervention through its integration of various technological innovations.
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.